Continuous Processing in the Context of a Broader Pharmaceutical Development Technology Strategy
Time: 10:20 am
day: Day Two
Details:
• Continuous processing value proposition for development vs. commercial organizations
• Roadmap approach facilitates parallel implementation of critical supporting Pharma 4.0 elements
• Modality-agnostic platform digital architectures and project frameworks facilitate rapid adoption
Speakers:
Mark Henson has a PhD in bio-inorganic chemistry from Stanford University. He has held various R&D roles involving PAT and predictive modeling across the pharmaceutical, embryology, and chemicals spaces at Pfizer, Molecular Biometrics LLC, and the ExxonMobil Chemical Co (respectively). He has also gained insight into various Quality and Regulatory topics in the GMP space…Read more